| |
Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk, plus Editorial Comment
|
| |
| |
AIDS Sept 1 2024
Trevillyan, Janine M.a,b; Dart, Anthonyc; Paul, Eldhod; Dewar, Elizabeth M.c; Hall, Victoria G.e; Hoy, Jennifer F.f
Download the PDF here
Download the PDF here
Abstract
This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676]........Perhaps, reflecting that aortic stiffness is more closely correlated with age and hypertension, rather than dyslipidaemia [9]. After the age of 50 years, there is near linear progression of PWV, with individuals with hypertension having a more rapid progression [10].
Editorial
Despite its limitations, the study by Trevillyan et al. underscores the increased risk for the development of cardiovascular adverse events that may be potentiated by the use of rosuvastatin in elderly PWH. Regardless of the treatment arms, a significant proportion of participants progressed from moderate to high-risk category for CVD, suggesting that additional mechanisms such as aging may likely be contributing to this progression. Thus, more investigations are required to elucidate and plan for successful interventional strategies in PWH.
|
|
| |
| |
|
|
|
